CELLF-BIO is a start-up company formed in North Carolina 2014. The company is currently funded by NIH-sponsored grants.
The mission of CELLF-BIO is to improve the healthcare outcome and quality of life for patients suffering from neurodegenerative diseases of the gut. The core business focus is bioengineering intrinsically innervated gastrointestinal tissue for implantation from autologous smooth muscle and neural progenitor cells. The company objectives are to bioengineer (a) intrinsically innervated sphincters to treat fecal and urinary incontinence and (b) stem cell therapy that can be endoscopically injected into the Pylorus to treat Gastroparesis. The company has begun a Phase 1 clinical trial (Q4, 2022) using a regenerative medicine approach implanting bioengineered IAS to treat patients with FI.
The mission of CELLF-BIO is to improve the healthcare outcome and quality of life for patients suffering from neurodegenerative diseases of the gut. The core business focus is bioengineering intrinsically innervated gastrointestinal tissue for implantation from autologous smooth muscle and neural progenitor cells. The company objectives are to bioengineer (a) intrinsically innervated sphincters to treat fecal and urinary incontinence and (b) stem cell therapy that can be endoscopically injected into the Pylorus to treat Gastroparesis. The company has begun a Phase 1 clinical trial (Q4, 2022) using a regenerative medicine approach implanting bioengineered IAS to treat patients with FI.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Virginia
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
BioSphincter (Bioengineered Autologous Internal Anal Sphincter)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
